Little Green Pharma’s subsidiary, Reset Mind Sciences, is commencing a trial in Western Australia using psilocybin to explore its effects on treatment-resistant depression. This trial, overseen by Professor Sean Hood, is expected to last 12 months. Little Green Pharma’s shares recently traded at 14.5 cents.